THOMAS JEFFERSON UNIVERSITY AND HOSPITALS

Friday, April 25, 2014Philadelphia, Pennsylvania

An All-Day Scientific and Clinical Symposium

A N N U A L S Y M P O S I U M

Scientific Update in Breast Cancer:Detection, Preclinical Modeling and Therapeutic Targeting

AN

A

LL

-D

AY

S

CIE

NT

IF

IC

A

ND

C

LIN

IC

AL

S

YM

PO

SIU

M

Sci

entifi

c U

pd

ate

in B

reas

t Can

cer:

Det

ecti

on, P

recl

inic

al M

odel

ing

and T

her

apeu

tic

Targ

etin

g

233

Sout

h 10

th S

tree

t Ro

om 10

50 B

LSB

Phila

delp

hia,

PA

1910

7

No

n-P

rofit

Org

aniz

atio

nU

S P

ost

age

PA

IDP

hila

del

phi

a, P

AP

erm

it #

276

Course Description

Breast cancer is one of the leading causes of cancer-related mortality in women both in the U.S. and worldwide. However, there have been dramatic advances in our understanding of the benefits of careful screening of high-risk individuals, the molecular biology of breast cancer, novel targets of importance, and the development of targeted therapies.

The latest advances in both breast cancer treatment and research – including innovations in molecular diagnostics, surgical management, systemic therapy and loco-regional radiation approaches – will be discussed Friday, April 25, 2014, at a breast cancer symposium at the Kimmel Cancer Center at Jefferson in Philadelphia.

The all-day, breast cancer symposium, part of an annual series at the Kimmel Cancer Center, will be held at the Bluemle Life Sciences Building, 233 S. 10th Street, beginning at 8:30 a.m.

“Treating breast cancer is a multidisciplinary effort, with input from a variety of specialists, such as pathologists, surgeons, radiation oncologists, and medical oncologists, who make decisions about patient treatment and care,” says Richard Pestell, MD, PhD, Director of the Kimmel Cancer Center at Jefferson and Professor and Chair of Cancer Biology at Jefferson Medical College of Thomas Jefferson University.

“This symposium is an opportunity for those players to come together and highlight the innovative discoveries we believe will be important for the next generation of therapeutics in breast cancer patients and to demonstrate how Jefferson plays a leading role in implementing these transformative approaches,” adds Dr. Massimo Cristofanilli, Director of the Jefferson Breast Care Center. A range of topics will be covered by top experts here at Jefferson and other institutions in the United States.

Learning Objectives

At the conclusion of this course, participants should be able to:

• Apply updated guidelines in screening for breast cancer

• Integrate new diagnostic options into their practices

• Integrate new treatment options into their practices

• Integrate new imaging modalities into their practices

• Apply updated guidelines in screening for breast cancer

Target Audience

Pathologists, Surgeons, Radiation Oncologists, and Medical Oncologists, and all other healthcare professionals involved in the study and the decision making process about breast cancer patients’ treatment and care.

Course Directors

Richard G. Pestell, MD, PhD, MB, BS, MBA, FACP, FRACP

Professor and Chair Department of Cancer Biology Jefferson Medical College

Director Kimmel Cancer Center

Conference Chair

Massimo Cristofanilli, MD, FACP

Professor Department of Medical Oncology Jefferson Medical College

Director Jefferson Breast Care Center

Deputy Director Translational Research

Director Solid Tumor Breast Program

Conference Co-Chair

Hallgeir Rui, MD, PhD

Professor Department of Cancer Biology Medical Oncology, and Pathology

Scientific Director Jefferson Breast Care Center

Leader Biology of Breast Cancer Program Kimmel Cancer Center Jefferson Medical College

Conference Co-Chair

Theodore Tsangaris, MD, FACS

Professor Department of Surgery

Surgical Director Jefferson Breast Care Center

Chief Breast Surgery Jefferson Medical College

Conference Co-Chair

Faculty Members

P. Rani Anné, MD

Associate Professor Department of Radiation Oncology Jefferson Medical College

Tiffany Avery, MD

Associate Professor Department of Medical Oncology Jefferson Medical College

Andrea Barsevick, PhD, RN

Associate Professor Division, Population Science Department of Medical Oncology Jefferson Medical College

Jenny C. Chang, MD

Professor Department of Medicine

Medical Director Lester and Sue Smith Breast Center Baylor College of Medicine

Alessandro Fatatis, MD, PhD

Professor Departments of Pharmacology & Physiology and Pathology and Laboratory Medicine Drexel University College of Medicine

Ann C. Klassen, PhD

Professor and Chair Department of Community Health and Prevention

Associate Dean for Research Public Health Drexel University College of Medicine

Edith P. Mitchell, MD, FACP

Clinical Professor of Medicine and Medical Oncology Department of Medical Oncology

Associate Director of Diversity Programs

Director Center for Elimination of Cancer Disparities Jefferson Medical College

Juan P. Palazzo, MD

Professor Department of Pathology, Anatomy and Cell Biology Jefferson Medical College

Nicole Simone, MD

Assistant Professor Department of Radiation Oncology Jefferson Medical College

W. Fraser Symmans, MD

Professor Department of Pathology

Director Research Operations Department of Pathology The University of Texas MD Anderson Cancer Center

Madhukar (Mathew) L. Thakur, MD

Professor Department of Radiology

Director Radiopharmaceutical & Nuclear Medicine Research Jefferson Medical College

Wendy A. Woodward, MD, PhD

Associate Professor Department of Radiation Oncology

Service Chief Breast Cancer Radiation Oncology Program The University of Texas MD Anderson Cancer Center

Hushan Yang, PhD

Assistant Professor Division, Population Science Department of Medical Oncology Jefferson Medical College

Accreditation

Jefferson Medical College of Thomas Jefferson University is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Jefferson Medical College of Thomas Jefferson University designates this live activity for a maximum of 7.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Society of Clinical Research Associates (SoCRA) accepts documentation of candidate participation in continuing education programs for re-certification if the clinical program is applicable to clinical research regulations, operations or management, or to the candidate’s clinical research therapeutic area.

8:30 a.m. – 8:35 a.m. Welcoming Remarks

Richard G. Pestell, MD, PhD, MB, BS, MBA, FACP, FRACP Professor and Chair, Cancer Biology, Director, Kimmel Cancer Center at Jefferson

Massimo Cristofanilli, MD, FACPProfessor of Medical Oncology, Director, Jefferson Breast Care Center Deputy Director, Translational Research, Director, Solid Tumor Breast Program

A N N U A L S Y M P O S I U M

Scientific Update in Breast Cancer:Detection, Preclinical Modeling and Therapeutic Targeting

Integration of Molecular Diagnostic Technologies in the Management of Breast CancerCo-Chairs: Juan P. Palazzo, MD, and Paolo M. Fortina, MD, PhD

8:35 a.m. – 9:10 a.m.

9:10 a.m. – 9:30 a.m.

9:30 a.m. – 9:50 a.m.

9:50 a.m. – 10:00 a.m.

10:00 a.m. – 10:20 a.m.

Keynote AddressThe Heterogeneity of TNBC in the Molecular EraW. Fraser Symmans, MD

Is There is Still a Role for Standard Histology in Breast Cancer Diagnostics?Juan P. Palazzo, MD

Molecular Diagnostics in Breast Cancer: Analyzing the Tissue, the Blood or Both?Massimo Cristofanilli, MD, FACP

Discussion

Coffee Break

Preclinical Models and Novel Molecular Therapies in Breast CancerCo-Chairs: Hallgeir Rui, MD, PhD, and Massimo Cristofanilli, MD, FACP

10:20 a.m. – 10:50 a.m.

10:50 a.m. – 11:10 a.m.

11:10 a.m. – 11:30 a.m.

11:30 a.m. – 11:50 a.m.

11:50 a.m. – 12:10 a.m.

12:10 a.m. – 12:20 p.m.

12:20 p.m. – 1:20 p.m.

Keynote AddressCharacterization and Targeting of Cancer Stem CellsJenny C. Chang, MD

Patient-derived Breast Cancer Xenograft Models in Prolactin-humanized MiceHallgeir Rui, MD, PhD

Novel Antagonists of CX3CR1 Impair the Homing of Breast Cancer Cells to the SkeletonAlessandro Fatatis, MD, PhD

CCR5 Inhibitors of MetastasisRichard G. Pestell, MD, PhD, MBBS, FRACP, MBA

Adaptive PARP-inhibitor TrialTiffany Avery, MD

Discussion

Lunch Break and Poster Session

Imaging Modalities and Loco-regional Therapies for Primary Breast CancerCo-Chairs: Theodore Tsangaris, MD, FACS, and Rani P. Anné, MD

1:20 p.m. – 1:50 p.m.

1:50 p.m. – 2:10 p.m.

2:10 p.m. – 2:30 p.m.

2:30 p.m. – 2:40 p.m.

2:40 p.m. – 2:50 p.m.

Keynote AddressRadiotherapy and Local Control in IBCWendy A. Woodward, MD, PhD

Molecular ImagingMadhukar (Mathew) L. Thakur, PhD

Evolving Role of Surgical Management of the Axilla in PBC Theodore Tsangaris, MD, FACS

Discussion

Break

Evolving Concepts in Epidemiology, Risk Assessment and Prevention of Breast CancerCo-Chairs: Andrea Barsevick, PhD, RN, and Edith P. Mitchell, MD, FACP

2:50 p.m. – 3:10 p.m.

3:10 p.m. – 3:30 p.m.

3:30 p.m. – 3:50 p.m.

3:50 p.m. – 4:10 p.m.

4:10 p.m. – 4:20 p.m.

4:20 p.m. – 4:30 p.m.

Outreach and MinoritiesEdith P. Mitchell, MD, FACP

EpidemiologyAnn C. Klassen, PhD

Caloric Restriction TrialNicole Simone, MD

Is There a Role for Molecular Risk Assessment in Breast Cancer?Hushan Yang, PhD

Discussion

Closing remarks

During the live symposium, follow us on Twitter at #KCCbreast14

Continental breakfast, breaks and lunch will be provided.

The Kimmel Cancer Center (KCC) was founded in 1991 with approximately 30 investigators in the basic sciences. Today, the KCC has approximately 150 members that include physicians and scientists dedicated to discovery and development of novel approaches for cancer treatment. The mission of the Kimmel Cancer Center, a National Cancer Institute-designated Cancer Center, is:

• to make transformational discoveries of the cellular and molecular biology of the malignant process and the individual’s and society’s response to it

• to effectively translate the latest research discoveries into clinical trials to provide the highest quality of care to all patients including those of diverse ethnic and racial populations

• to provide expert and humanitarian care to cancer patients, their families, and those at risk

U.S.News & World Report recognizes Jefferson as one of the best hospitals in the nation for Cancer care. Jefferson is also a Blue Distinction Center for Complex and Rare Cancers. Blue Distinction is a nationwide program of the Blue Cross and Blue Shield Association, recognizing specialty centers that offer the best practices and standards of cancer care.

The Kimmel Cancer Center is proud of its status as a National Cancer Institute-designated Cancer Center. The NCI-designated cancer centers were established to be national leaders in cancer treatment, research, and

education. To gain a designation of the highest ranking given by the NCI, a center must meet specific criteria:

• A strong core of basic laboratory research in several fields, such as biology, chemistry, immunology and molecular genetics

• A mechanism for transferring research findings into clinical practice

• A record of innovative clinical research studies in the community served by the center

• A program of high-priority clinical trials for therapies with unusual promise

• A program of cancer prevention and control research

• A program of research training and continuing education for health care professionals

• A wide range of cancer information services for patients, health professionals and the surrounding community

• A commitment to community services and outreach activities related to cancer prevention and control

Finally, the NCI Cancer Advisory Board, whose members are appointed by the President of the United States to oversee the NCI’s programs and policies, must recommend approval for a center to receive the comprehensive designation. The center must repeat an external review of the steps above every three to five years.

About the Kimmel Cancer Center at Jefferson

Aria HealthAlfred I. DuPont Institute for ChildrenEinstein Medical Center PhiladelphiaEphrata Community HospitalHem & Onc Associates of NE PA PCHudson Valley Oncology AssociatesInspira Medical Center WoodburyJefferson Hospital for NeurosciencesJennersville Regional Hospital

Kimmel Cancer Center at JeffersonMercy Fitzgerald HospitalMercy Philadelphia HospitalMercy Suburban HospitalMethodist HospitalNazareth HospitalNortheast Radiation Oncology CenterPocono Medical CenterReading Hospital

Riddle HospitalSt. Francis Medical CenterSt. Francis Hospital (Wilmington)Sacred Heart HospitalSparta Cancer CenterTrinitas Regional Medical CenterUpper Delaware Valley Cancer CenterWills Eye Institute

About the Jefferson Kimmel Cancer Center Network

In 1993, the Jefferson Kimmel Cancer Center Network was established to provide patients in its member hospitals access to the latest developments in cancer research, technology and treatment. Jefferson’s Kimmel Cancer Center offers patients at member hospitals the opportunity to participate in clinical trials utilizing state-of-the-science approaches to preventing, diagnosing and treating cancer. Physicians in the network take advantage of each other’s consultative knowledge, and patients have a greater opportunity to benefit from innovative treatment options close to home.

N e t w o r k M e m b e r s

About the Jefferson Kimmel Cancer Center Consortium

In May 2012, Drexel University (DU) and Thomas Jefferson University (TJU) established an overarching General Research Affiliation Agreement and a specific Cancer Research Affiliation Agreement to form a cancer research consortium with the Kimmel Cancer Center (KCC) at TJU. Lankenau Institute for Medical Research (LIMR) is also a formal consortium member of the KCC. As part of the Consortium, all faculty and students from both institutions are welcome to participate in seminars and networking activities. S

cien

tific

Upd

ate

in B

reas

t C

ance

r: D

etec

tion,

Pre

clin

ical

Mod

elin

g an

d Th

erap

eutic

Tar

getin

gFri

day,

Apri

l 25,

201

4 •

8:3

0 a

.m.

to 4

:30 p

.m.

Blu

emle

Life

Sci

ence

s B

uild

ing

– 23

3 S

. 10t

h S

tree

t, P

hila

delp

hia,

PA

191

07

o M

ale

o F

emal

e

Last

Nam

e Fi

rst

Nam

e M

I

Title

(Dr.,

Mr.,

Ms.

) P

erso

nal T

itle

(II, J

r.)

Deg

ree

(MD

, MS

N, B

SN

, MB

A, P

hD, e

tc.)

Sp

ecia

lty

Affi

liatio

n/O

rgan

izat

ion

Mai

ling

Ad

dre

ss

City

S

tate

Z

ip

Tele

pho

ne o

Wor

k o

Hom

e o

Cel

l Fa

x E

mai

l Ad

dre

ss

n n

n n

Web

ID: P

leas

e pr

ovid

e th

e la

st fo

ur d

igits

of y

our S

ocia

l Sec

urity

Num

ber a

s yo

ur W

eb ID

. Thi

s w

ill al

low

you

to a

cces

s yo

ur C

ME

tran

scrip

t at a

ny ti

me

afte

r the

cou

rse.

Regis

trati

on F

ees

n $

50

Jeffe

rson

Pra

ctic

ing

Phy

sici

ans

and

Affi

liate

s

n $

30

Jeffe

rson

Res

earc

hers

, Nur

ses,

Allie

d H

ealth

Pro

fess

iona

ls a

nd A

ffilia

tes

n $

100

Non

-Jef

fers

on P

ract

icin

g P

hysi

cian

s

n $

50

Non

-Jef

fers

on R

esea

rche

rs, N

urse

s an

d A

llied

Hea

lth P

rofe

ssio

nals

,

Ret

ired

Phy

sici

ans

n $

300

Indu

stry

/Oth

ers:

Thi

s ca

tego

ry d

efine

s an

y pe

rson

em

ploy

ed b

y a

no

n-su

ppor

ting

for-

profi

t org

aniz

atio

n in

clud

ing

biot

echn

olog

y, fi

nanc

ial

and

phar

mac

eutic

al

To r

egis

trat

ion

ple

ase

use

on

e of

th

e fo

llow

ing

op

tion

s:

Onl

ine:

ww

w.k

imm

elca

ncer

cent

er.o

rg/s

ymp

osi

um

Fax

: Yo

u m

ay fa

x th

is fo

rm w

ith c

redi

t car

d in

form

atio

n to

215

- 503

- 933

4

Mai

l: M

ildre

d D

. Har

den

Kim

mel

Can

cer

Cen

ter

at J

effe

rson

23

3 S

outh

10t

h S

tree

t, S

uite

105

0

Phi

lade

lphi

a, P

A 1

9107

Pay

men

t: P

leas

e m

ake

chec

k pa

yabl

e to

Tho

mas

Jef

fers

on

Uni

vers

ity, o

r pr

ovid

e cr

edit

card

info

rmat

ion.

o C

heck

enc

lose

d. C

heck

Num

ber:

o V

isa

o M

aste

rCar

d A

mou

nt:

Car

dho

lder

’s N

ame

Ad

dre

ss o

n C

red

it C

ard

(if d

iffer

ent

from

ab

ove)

Acc

ount

Num

ber

E

xpira

tion

Dat

e

Car

dho

lder

’s S

igna

ture

If yo

u ha

ve a

ny s

peci

al n

eeds

, ple

ase

call

Mild

red

D. H

arde

n at

215

- 955

- 819

5.

Regis

trati

on

Dead

lin

e is

Ap

ril 1

8,

201

4

Re

gis

te

R n

ow

!